MSE
ALXN

MUFG Securities EMEA’s Alexion Pharmaceuticals ALXN Stock Holding History

MUFG Securities EMEA’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-406,000
Closed -$74.6M – 380
2021
Q2 		$74.6M Buy
406,000
+148,000
+57% +$25.4M 0.71% 26
2021
Q1 		$39.5M Buy
+258,000
New +$39.9M 0.32% 71
2020
Q2 		– Sell
-112,000
Closed -$10.1M – 532
2020
Q1 		$10.1M Buy
112,000
+66,000
+143% +$6.48M 0.1% 147
2019
Q4 		$4.97M Buy
46,000
+38,400
+505% +$4.11M 0.04% 279
2019
Q3 		$744K Sell
7,600
-67,400
-90% -$7.6M 0.01% 286
2019
Q2 		$9.82M Buy
+75,000
New +$9.67M 0.1% 134
2018
Q4 		– Sell
-6,042
Closed -$840K – 761
2018
Q3 		$840K Buy
6,042
+5,793
+2,327% +$727K 0.01% 361
2018
Q2 		$31K Buy
+249
New +$29.1K ﹤0.01% 347

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

MUFG Securities EMEA's ALXN Position: Q3 2021 in Review

MUFG Securities EMEA sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 406,000 shares — an estimated $74.6M sold.

MUFG Securities EMEA first reported a position in ALXN in Q2 2018 and held it in 8 quarters. The position peaked at $74.6M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • MUFG Securities EMEA reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • MUFG Securities EMEA sold 406,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $74.6M.
  • MUFG Securities EMEA first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 8 quarters.
  • MUFG Securities EMEA's Alexion Pharmaceuticals position peaked at $74.6M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on MUFG Securities EMEA's 13F filing for Q3 2021, filed 12 Nov 2021.